- Home
- MFH vs PHAT Comparison
MFH vs PHAT Comparison
Compare MFH & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFH
- PHAT
- Stock Information
- Founded
- MFH 2011
- PHAT 2018
- Country
- MFH United States
- PHAT United States
- Employees
- MFH N/A
- PHAT N/A
- Industry
- MFH Finance: Consumer Services
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- MFH Finance
- PHAT Health Care
- Exchange
- MFH Nasdaq
- PHAT Nasdaq
- Market Cap
- MFH 822.0M
- PHAT 963.9M
- IPO Year
- MFH N/A
- PHAT 2019
- Fundamental
- Price
- MFH $12.42
- PHAT $13.05
- Analyst Decision
- MFH
- PHAT Strong Buy
- Analyst Count
- MFH 0
- PHAT 5
- Target Price
- MFH N/A
- PHAT $17.60
- AVG Volume (30 Days)
- MFH 311.3K
- PHAT 1.1M
- Earning Date
- MFH 12-04-2025
- PHAT 10-30-2025
- Dividend Yield
- MFH N/A
- PHAT N/A
- EPS Growth
- MFH N/A
- PHAT N/A
- EPS
- MFH N/A
- PHAT N/A
- Revenue
- MFH $960,967.00
- PHAT $147,190,000.00
- Revenue This Year
- MFH N/A
- PHAT $213.65
- Revenue Next Year
- MFH N/A
- PHAT $91.41
- P/E Ratio
- MFH N/A
- PHAT N/A
- Revenue Growth
- MFH 65.39
- PHAT 460.30
- 52 Week Low
- MFH $1.20
- PHAT $2.21
- 52 Week High
- MFH $36.77
- PHAT $19.05
- Technical
- Relative Strength Index (RSI)
- MFH 47.80
- PHAT 49.94
- Support Level
- MFH $8.41
- PHAT $13.11
- Resistance Level
- MFH $11.98
- PHAT $14.22
- Average True Range (ATR)
- MFH 1.93
- PHAT 1.00
- MACD
- MFH -0.25
- PHAT -0.11
- Stochastic Oscillator
- MFH 70.86
- PHAT 4.88
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.